Supernus Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 11 trials

TrialDrugs studiedStatusPrimary completion
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)NCT02736656SPN-812Active not recruiting2026-12Estimated
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHDNCT04143217SPN-812Completed2022-07-26Actual
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)NCT03665038BrexanoloneCompleted2021-01-08Actual
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)NCT02618434SPN-810 (18 mg), SPN-810 (36 mg)Completed2019-11-15Actual
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)NCT02618408SPN-810 (18 mg), SPN-810 (36 mg)Completed2019-09-04Actual
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)NCT02942004SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/hCompleted2017-09-24Actual
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)NCT02942017SAGE-547 90 μg/kg/hCompleted2017-09-17Actual
A Study With SAGE-547 for Super-Refractory Status EpilepticusNCT02477618SAGE-547Completed2017-07-18Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseNCT05655520SAGE-718Terminated2025-01-20Actual
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)NCT02691182SPN-810Terminated2021-05Actual
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentNCT03597503SPN-810Terminated2020-01-22Actual

Phase 2 15 trials

TrialDrugs studiedStatusPrimary completion
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyNCT05518578SPN-817Recruiting2027-12-31Estimated
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresNCT06798896SPN-817Recruiting2027-08Estimated
Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderNCT07226661SPN-821 2400 mgRecruiting2026-12-31Estimated
SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresNCT07141329SPN-817Enrolling by invitation2027-12-31Estimated
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)NCT05107128SAGE-718Completed2024-09-04Actual
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT05619692SAGE-718Completed2024-06-05Actual
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseNCT05358821SAGE-718Completed2024-02-29Actual
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentNCT05318937SAGE-718Completed2024-01-17Actual
An Open-Label Study Evaluating Brexanolone in Adults With TinnitusNCT05645432BrexanoloneCompleted2023-11-21Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)NCT04476017SAGE-718Completed2022-03-25Actual
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)NCT04602624SAGE-718Completed2021-09-28Actual
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionNCT02614547SAGE-547Completed2016-06-22Actual
Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionNCT02285504SAGE-547Completed2015-06-05Actual
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsNCT00626236SPN-810Completed2009-09-23Actual
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHDNCT03638466Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810Terminated2019-11-07Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters